ArticleMedicine2026
Severe exfoliative dermatitis induced by apalutamide in a mHSPC patient: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
rationaleApalutamide is a generation androgen antagonist for the treatment of metastatic hormone sensitive prostate cancer and non-metastatic castration resistant prostate cancer. Skin adverse reactions caused by apalutamide are mostly rashes and maculopapules. PATIENT CONCERNS: There are a few reports about exfoliative dermatitis caused by apalutamide. DIAGNOSES: Severe exfoliative dermatitis induced by apalutamide.
interventionsGamma globulin, cefoperazone sulbactam sodium, albumin, ebastine, loratadine, hydrocortisone cream, and 3% boric acid lotion. OUTCOMES: Whole-body skin was red, without exudation, and with a small amount of desquamation. LESSONS: The incidence of exfoliative dermatitis due to apalutamide is low but severe, and if a serious adverse skin reaction is suspected, apalutamide needs to be discontinued immediately and treated accordingly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.